---

Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.

The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.

#news #health #medicine #cholesterol #GeneTherapy #GeneEditing

One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare nytimes.com/2026/05/25/health/…